Acta Biologica Hungarica
Volume/Issue:
Volume 61: Issue 3
Antifungal activity of statins and their interaction with amphotericin B against clinically important Zygomycetes
Authors:
L. Galgóczy University of Szeged Department of Microbiology, Faculty of Science and Informatics Szeged Hungary

Search for other papers by L. Galgóczy in
Current site
Google Scholar
PubMed Close
,
Gyöngyi Lukács University of Szeged Department of Microbiology, Faculty of Science and Informatics Szeged Hungary

Search for other papers by Gyöngyi Lukács in
Current site
Google Scholar
PubMed Close
,
Ildikó Nyilasi University of Szeged Department of Microbiology, Faculty of Science and Informatics Szeged Hungary

Search for other papers by Ildikó Nyilasi in
Current site
Google Scholar
PubMed Close
,
T. Papp University of Szeged Department of Microbiology, Faculty of Science and Informatics Szeged Hungary

Search for other papers by T. Papp in
Current site
Google Scholar
PubMed Close
, and
Cs. Vágvölgyi University of Szeged Department of Microbiology, Faculty of Science and Informatics Szeged Hungary

Search for other papers by Cs. Vágvölgyi in
Current site
Google Scholar
PubMed Close
Pages:
356–365
Online Publication Date:
19 Aug 2010
Publication Date:
01 Sep 2010
Article Category:
Research Article
DOI:
https://doi.org/10.1556/abiol.61.2010.3.11
Keywords:
Statin; amphotericin B; Zygomycetes; drug interaction; synergism
Restricted access

The in vitro antifungal activity of different statins and the combinations of the two most effective ones (fluvastatin and rosuvastatin) with amphotericin B were investigated in this study on 6 fungal isolates representing 4 clinically important genera, namely Absidia, Rhizomucor, Rhizopus and Syncephalastrum . The antifungal effects of statins revealed substantial differences. The synthetic statins proved to be more effective than the fungal metabolites. All investigated strains proved to be sensitive to fluvastatin. Fluvastatin and rosuvastatin acted synergistically and additively with amphotericin B in inhibiting the fungal growth in clinically available concentration ranges. Results suggest that statins combined with amphotericin B have a therapeutic potential against fungal infections caused by Zygomycetes species.

  • Almyroudis, N. G., Sutton, D. A., Fothergill, A. W., Rinaldi, M. G., Kusne, S. (2007) In vitro susceptibilities of 217 clinical isolates of Zygomycetes to conventional and new antifungal agents. Antimicrob. Agents. Ch. 51 , 2587–2590.

    Kusne S. , 'In vitro susceptibilities of 217 clinical isolates of Zygomycetes to conventional and new antifungal agents ' (2007 ) 51 Antimicrob. Agents. Ch. : 2587 -2590 .

    • Search Google Scholar

  • Bellosta, S., Paoletti, R., Corsini, A. (2004) Safety of statins: Focus on clinical pharmacokinetics and drug interactions. American Heart Association, Circulation 109 , III-50–III-57, DOI: 10.1161/01.CIR.0000131519.15067.1f

    Corsini A. , 'Safety of statins: Focus on clinical pharmacokinetics and drug interactions ' (2004 ) 109 American Heart Association, Circulation : III-50 -III-57 .

    • Search Google Scholar

  • Buemi, M., Floccari, F., Nostro, L., Campo, S., Caccamo, C., Sturiale, A., Aloisi, C., Giacobbe, M. S., Frisina, N. (2007) Statins in the prevention of cardiovascular events in patients with renal failure. Cardiovasc. Haematol. Disord. Drug. Targets 7 , 7–13.

    Frisina N. , 'Statins in the prevention of cardiovascular events in patients with renal failure ' (2007 ) 7 Cardiovasc. Haematol. Disord. Drug. Targets : 7 -13 .

    • Search Google Scholar

  • Chamilos, G., Lewis, R. E., Kontoyiannis, D. P. (2006) Lovastatin has significant activity against Zygomycetes and interacts synergistically with voriconazole. Antimicrob. Agents. Ch. 50 , 96–103.

    Kontoyiannis D. P. , 'Lovastatin has significant activity against Zygomycetes and interacts synergistically with voriconazole ' (2006 ) 50 Antimicrob. Agents. Ch. : 96 -103 .

    • Search Google Scholar

  • Chayakulkeeree, M., Ghannoum, M. A., Perfect, J. R. (2006) Zygomycosis: the re-emerging fungal infection. Eur. J. Clin. Microbiol. Infect. Dis. 25 , 215–229.

    Perfect J. R. , 'Zygomycosis: the re-emerging fungal infection ' (2006 ) 25 Eur. J. Clin. Microbiol. Infect. Dis. : 215 -229 .

    • Search Google Scholar

  • Cordle, A., Koenigsknecht-Talboo, J., Wilkinson, B., Limpert, A., Landreth, G. (2005) Mechanism of statin-mediated inhibition of small G-protein function. J. Biol. Chem. 280 , 34202–34209.

    Landreth G. , 'Mechanism of statin-mediated inhibition of small G-protein function ' (2005 ) 280 J. Biol. Chem. : 34202 -34209 .

    • Search Google Scholar

  • Corsini, A., Bellosta, S., Baetta, R., Fumagallia, R., Paolettia, R., Berninib, F. (1999) New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacolo. Therapeut. 84 , 413–428.

    Berninib F. , 'New insights into the pharmacodynamic and pharmacokinetic properties of statins ' (1999 ) 84 Pharmacolo. Therapeut. : 413 -428 .

    • Search Google Scholar

  • Corsini, A., Bellosta, A., Davidson, H. M. (2005) Pharmacokinetic interactions between statins and fibrates. Am. J. Cardiol. 96 , 44–49.

    Davidson H. M. , 'Pharmacokinetic interactions between statins and fibrates ' (2005 ) 96 Am. J. Cardiol. : 44 -49 .

    • Search Google Scholar

  • Eliopoulos, G. M., Moellering, R. C. (1996) Antimicrobial combinations. In: Lorian, V. (ed.) Antibiotics in Laboratory Medicine . 4th edn. Williams and Wilkins, Baltimore, MD, pp. 330–396.

    Moellering R. C. , '', in Antibiotics in Laboratory Medicine , (1996 ) -.

  • Galgóczy, L., Papp, T., Lukács, Gy., Leiter, É., Pócsi, I., Vágvölgyi, Cs. (2007) Interactions between statins and Penicillium chrysogenum antifungal protein (PAF) to inhibit the germination of sporangiospores of different sensitive Zygomycetes . FEMS Microbiol. Lett. 270 , 109–115.

    Vágvölgyi Cs. , 'Interactions between statins and Penicillium chrysogenum antifungal protein (PAF) to inhibit the germination of sporangiospores of different sensitive Zygomycetes ' (2007 ) 270 FEMS Microbiol. Lett. : 109 -115 .

    • Search Google Scholar

  • Galgóczy, L., Papp, T., Vágvölgyi, Cs. (2009) In vitro interaction between suramin and fluvastatin against clinically important Zygomycetes. Mycoses. 52 , 447–453.

    Vágvölgyi Cs. , 'In vitro interaction between suramin and fluvastatin against clinically important Zygomycetes ' (2009 ) 52 Mycoses. : 447 -453 .

    • Search Google Scholar

  • Gallagher, C. G., Ashley, E. S. D., Drew, R. H., Perfect, J. R. (2003) Antifungal pharmacotherapy for invasive mould infections. Expt. Opin. Pharmacother. 4 , 147–164.

    Perfect J. R. , 'Antifungal pharmacotherapy for invasive mould infections ' (2003 ) 4 Expt. Opin. Pharmacother. : 147 -164 .

    • Search Google Scholar

  • Ghittoni, R., Patrussi, L., Pirozzi, K., Pellegrini, M., Lazzerini, P. E., Capecchi, P. L., Pasini, F. L., Baldari, C. T. (2005) Simvastatin inhibits T cell activation by selectively impairing the function of Ras superfamily GTPases. The FASEB Journal 19 , 605–607.

    Baldari C. T. , 'Simvastatin inhibits T cell activation by selectively impairing the function of Ras superfamily GTPases ' (2005 ) 19 The FASEB Journal : 605 -607 .

    • Search Google Scholar

  • Groll, A. H., Giri, N., Petraitis, V., Petraitiene, R., Candelario, M., Bacher, J. S., Piscitelli, S. C, Walsh, T. J. (2000) Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans . J. Infect. Dis. 182 , 274–282.

    Walsh T. J. , 'Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans ' (2000 ) 182 J. Infect. Dis. : 274 -282 .

    • Search Google Scholar

  • Kajinami, K., Takekoshi, N., Saito, Y. (2003) Pitavastatin: Efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor. Cardiovasc. Drug. Rev. 21 , 199–215.

    Saito Y. , 'Pitavastatin: Efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor ' (2003 ) 21 Cardiovasc. Drug. Rev. : 199 -215 .

    • Search Google Scholar

  • Larabi, M., Pages, N., Pons, F., Appel, M., Gulik, A., Schlatter, J., Bouvet, S., Barratt, G. (2004) Study of the toxicity of a new lipid complex formulation of amphotericin B. J. Antimicrob. Chemoth. 53 , 81–88.

    Barratt G. , 'Study of the toxicity of a new lipid complex formulation of amphotericin B ' (2004 ) 53 J. Antimicrob. Chemoth. : 81 -88 .

    • Search Google Scholar

  • Liao, J. K. (2002) Isoprenoids as mediators of the biological effects of statins. J. Clin. Invest. 110 , 285–288.

    Liao J. K. , 'Isoprenoids as mediators of the biological effects of statins ' (2002 ) 110 J. Clin. Invest. : 285 -288 .

    • Search Google Scholar

  • Liao, J. K., Laufs, U. (2005) Pleiotropic effects of statins. Annu. Rev. Pharmacol. Toxicol. 45 , 89–118.

    Laufs U. , 'Pleiotropic effects of statins ' (2005 ) 45 Annu. Rev. Pharmacol. Toxicol. : 89 -118 .

    • Search Google Scholar

  • Lorenz, R. T., Parks, L. W. (1990) Effects of Lovastatin (Mevinolin) on sterol levels and on activity of azoles in Saccharomyces cerevisiae. Antimicrob. Agents Chemother. 34 , 1660–1665.

    Parks L. W. , 'Effects of Lovastatin (Mevinolin) on sterol levels and on activity of azoles in Saccharomyces cerevisiae ' (1990 ) 34 Antimicrob. Agents Chemother. : 1660 -1665 .

    • Search Google Scholar

  • Lukács, Gy., Papp, T., Nyilasi, I., Nagy, E., Vágvölgyi, Cs. (2004) Differentiation of Rhizomucor species on the basis of their different sensitivities to lovastatin. J. Clin. Microbiol. 42 , 5400–5402.

    Vágvölgyi Cs. , 'Differentiation of Rhizomucor species on the basis of their different sensitivities to lovastatin ' (2004 ) 42 J. Clin. Microbiol. : 5400 -5402 .

    • Search Google Scholar

  • Lukács, Gy., Papp, T., Somogyvári, F., Csernetics, Á., Nyilasi, I., Vágvölgyi, Cs. (2008) Cloning of the Rhizomucor miehei 3-hydroxy-3-methylglutaryl-coenzyme A reductase gene and its heterologous expression in Mucor circinelloides . Anton. Leeuw. Int. J. G. 95 , 55–64.

    Vágvölgyi Cs. , 'Cloning of the Rhizomucor miehei 3-hydroxy-3-methylglutaryl-coenzyme A reductase gene and its heterologous expression in Mucor circinelloides ' (2008 ) 95 Anton. Leeuw. Int. J. G. : 55 -64 .

    • Search Google Scholar

  • Miida, T., Hirayama, S., Nakamura, Y. (2004) Cholesterol-independent effects of statins and new therapeutic strategies: ischemic stroke and dementia. J. Atheroscler. Thromb. 11 , 253–264.

    Nakamura Y. , 'Cholesterol-independent effects of statins and new therapeutic strategies: ischemic stroke and dementia ' (2004 ) 11 J. Atheroscler. Thromb. : 253 -264 .

    • Search Google Scholar

  • Minassian, B., Huczko, E., Washo, T., Bonner, T., Fung-Tomc, J. (2003) In vitro activity of ravuconazole against Zygomycetes, Scedosporium and Fusarium isolates. Clin. Microbiol. Infect. 9 , 1250–1252.

    Fung-Tomc J. , 'In vitro activity of ravuconazole against Zygomycetes, Scedosporium and Fusarium isolates ' (2003 ) 9 Clin. Microbiol. Infect. : 1250 -1252 .

    • Search Google Scholar

  • Moreno, A. B., del Pozo, A. M., Borja, M., San Segudo, B. (2003) Activity of the antifungal protein from Aspergillus giganteus against Botrytis cinerea . Phytopathology 93 , 1344–1353.

    San Segudo B. , 'Activity of the antifungal protein from Aspergillus giganteus against Botrytis cinerea ' (2003 ) 93 Phytopathology : 1344 -1353 .

    • Search Google Scholar

  • National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard. (2002) NCCLS document M38-A . NCLS, Wayne, Pennsylvania, USA.

    '', in NCCLS document M38-A , (2002 ) -.

  • Nucci, M. (2003) Emerging moulds: Fusarium , Scedosporium and Zygomycetes in transplant recipients. Curr. Opin. Infect. Dis. 16 , 607–612.

    Nucci M. , 'Emerging moulds: Fusarium, Scedosporium and Zygomycetes in transplant recipients ' (2003 ) 16 Curr. Opin. Infect. Dis. : 607 -612 .

    • Search Google Scholar

  • Prabhu, R. M., Patel, R. (2004) Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin. Microbiol. Infect. 10(S1) , 31–47.

    Patel R. , 'Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment ' (2004 ) 10 Clin. Microbiol. Infect. : 31 -47 .

    • Search Google Scholar

  • Ribes, J. A., Vanhover-Sams, C. L., Baker, D. J. (2000) Zygomycetes in human disease. Clin. Microbiol. Rev. 13 , 236–301.

    Baker D. J. , 'Zygomycetes in human disease ' (2000 ) 13 Clin. Microbiol. Rev. : 236 -301 .

    • Search Google Scholar

  • Rodriguez-Tudela, J. L., Arendrup, M. C., Arikan, S., Barchiesi, F., Bille, J., Chryssanthou, E., Cuenca-Estrella, M., Dannaoui, E., Denning, D. W., Donnelly, J. P., Fegeler, W., Lass-Flörl, C., Moore, C., Richardson, M., Gaustad, P., Schmalreck, A., Velegraki, A., Verweij, P. (2007) Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds. EUCAST Discussion Document . European Committee on Antimicrobial Susceptibility Testing, Basel, Switzerland.

    Verweij P. , '', in EUCAST Discussion Document , (2007 ) -.

  • Rogers, T. R. (2008) Treatment of zygomycosis: current and new options. J. Antimicrob. Chemoth. 61(S1) , 35–39.

    Rogers T. R. , 'Treatment of zygomycosis: current and new options ' (2008 ) 61 J. Antimicrob. Chemoth. : 35 -39 .

    • Search Google Scholar

  • Roze, L. V., Linz. J. E. (1998) Lovastatin triggers an apoptosis-like cell death process in the fungus Mucor racemosus . Fungal. Genet. Biol. 25 , 119–133.

    Linz J. E. , 'Lovastatin triggers an apoptosis-like cell death process in the fungus Mucor racemosus ' (1998 ) 25 Fungal. Genet. Biol. : 119 -133 .

    • Search Google Scholar

  • Sabatelli, F., Patel, R., Mann, P. A., Mendrick, C. A., Norris, C. C., Hare, R., Loebenberg, D., Black, T. A., McNicholas, P. M. (2006) In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob. Agents Ch. 50 , 2009–2015.

    McNicholas P. M. , 'In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts ' (2006 ) 50 Antimicrob. Agents Ch. : 2009 -2015 .

    • Search Google Scholar

  • Schachter, M. (2004) Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fund. Clin. Pharmacol. 19 , 117–125.

    Schachter M. , 'Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update ' (2004 ) 19 Fund. Clin. Pharmacol. : 117 -125 .

    • Search Google Scholar

  • Sun, H.-Y., Singh, N. (2009) Antimicrobial and immunomodulatory attributes of statins: Relevance in solid-organ transplant recipients. Clin. Infect. Dis. 48 , 745–755.

    Singh N. , 'Antimicrobial and immunomodulatory attributes of statins: Relevance in solid-organ transplant recipients ' (2009 ) 48 Clin. Infect. Dis. : 745 -755 .

    • Search Google Scholar

  • Takó, M., Csernetics, Á. (2005) Genotypic analysis of variability in zygomycetes. Acta Biol. Hung. 56 , 345–357.

    Csernetics , 'Genotypic analysis of variability in zygomycetes ' (2005 ) 56 Acta Biol. Hung. : 345 -357 .

    • Search Google Scholar

  • Vazquez, J. A. (2007) Combination antifungal therapy: the new frontier. Future Microbiol. 2 , 115–139.

    Vazquez J. A. , 'Combination antifungal therapy: the new frontier ' (2007 ) 2 Future Microbiol. : 115 -139 .

    • Search Google Scholar

  • Vicente, M. F., Basilio, A., Cabello, A., Pelaez, F. (2003) Microbial natural products as a source of antifungals. Clin. Microbiol. Infect. 9 , 15–32.

    Pelaez F. , 'Microbial natural products as a source of antifungals ' (2003 ) 9 Clin. Microbiol. Infect. : 15 -32 .

    • Search Google Scholar

  • Walsh, T. J., Groll, A., Hiemenz, J., Fleming, R., Roilides, E., Anaissie, E. (2004) Infections due to emerging and uncommon medically important fungal pathogens. Clin. Microbiol. Infect. 10(S1) , 48–66.

    Anaissie E. , 'Infections due to emerging and uncommon medically important fungal pathogens ' (2004 ) 10 Clin. Microbiol. Infect. : 48 -66 .

    • Search Google Scholar
  • Collapse
  • Expand
Cover Acta Biologica Hungarica
Acta Biologica Hungarica
Print ISSN:
0236-5383
Online ISSN:
1588-256X

Senior editors

Editor(s)-in-Chief: Elekes, Károly

Editorial Board

    1. Csányi, Vilmos (Göd)
    1. Dudits, Dénes (Szeged)
    1. Falus, András (Budapest)
    1. Fischer, Ernő (Pécs)
    1. Gábriel, Róbert (Pécs)
    1. Gulya, Károly (Szeged)
    1. Gulyás, Balázs (Stockholm)
    1. Hajós, Ferenc (Budapest)
    1. Hámori, József (Budapest)
    1. Heszky, László (Gödöllő)
    1. Hideg, Éva (Szeged)
    1. E. Ito (Sanuki)
    1. Janda, Tibor (Martonvásár)
    1. Kavanaugh, Michael P. (Missoula)
    1. Kása, Péter (Szeged)
    1. Klein, Éva (Stockholm)
    1. Kovács, János (Budapest)
    1. Brigitte Mauch-Mani (Neuchâtel)
    1. Nässel, Dick R. (Stockholm)
    1. Nemcsók, János (Szeged)
    1. Péczely, Péter (Gödöllő)
    1. Roberts, D. F. (Newcastle-upon-Tyne)
    1. Sakharov, Dimitri A. (Moscow)
    1. Singh, Meharvan (Fort Worth)
    1. Sipiczky, Mátyás (Debrecen)
    1. Szeberényi, József (Pécs)
    1. Székely, György (Debrecen)
    1. Tari, Irma (Szeged)
    1. Vágvölgyi, Csaba (Szeged),
    1. L. Zaborszky (Newark)

 

Acta Biologica Hungarica
P.O. Box 35
H-8237 Tihany, Hungary
Phone: (36 87) 448 244 ext. 103
Fax: (36 87) 448 006
E-mail: elekes@tres.blki.hu

Indexing and Abstracting Services:

  • Biological Abstracts
  • BIOSIS Previews
  • CAB Abstracts
  • Chemical Abstracts
  • Current Contents: Agriculture
  • Biology and Environmental Sciences
  • Elsevier BIOBASE
  • Global Health
  • Index Medicus
  • Index Veterinarius
  • Medline
  • Referativnyi Zhurnal
  • Science Citation Index
  • Science Citation Index Expanded (SciSearch)
  • SCOPUS
  • The ISI Alerting Services
  • Zoological Abstracts

 

Acta Biologica Hungarica
Language English
Size  
Year of
Foundation		 1950
Publication
Programme		 changed title
Volumes
per Year		  
Issues
per Year		  
Founder Magyar Tudományos Akadémia
Founder's
Address		 H-1051 Budapest, Hungary, Széchenyi István tér 9.
Publisher Akadémiai Kiadó
Publisher's
Address		 H-1117 Budapest, Hungary 1516 Budapest, PO Box 245.
Responsible
Publisher		 Chief Executive Officer, Akadémiai Kiadó
ISSN 0236-5383 (Print)
ISSN 1588-256X (Online)

Monthly Content Usage

Abstract Views Full Text Views PDF Downloads
Dec 2024 27 0 0
Jan 2025 55 1 1
Feb 2025 55 0 0
Mar 2025 55 1 2
Apr 2025 32 0 0
May 2025 1 0 0
Jun 2025 0 0 0